Drug interactions
Lorlatinib + Pralsetinib
Severity: Major
Lorlatinib and Pralsetinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pralsetinib is cleared by CYP3A4, and lorlatinib induces CYP3A. Lower pralsetinib concentrations may reduce antitumor efficacy in RET-driven cancers.
What this interaction means in plain words
Lorlatinib and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Lorlatinib belongs to Oncology; Pralsetinib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing pralsetinib metabolism.
What to do
Avoid combining; if unavoidable, adjust pralsetinib dose per labeling for CYP3A inducers and monitor tumor response.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Pralsetinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Pralsetinib
Frequently asked questions
Can I take Lorlatinib with Pralsetinib?
MediHelp rates the interaction as major. Lorlatinib and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pralsetinib is cleared by CYP3A4, and lorlatinib induces CYP3A. Lower pralsetinib concentrations may reduce antitumor efficacy in RET-driven cancers.
How serious is the interaction between Lorlatinib and Pralsetinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining; if unavoidable, adjust pralsetinib dose per labeling for CYP3A inducers and monitor tumor response.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
